JAGX — Jaguar Health Income Statement
0.000.00%
Last trade - 00:00
- $43.34m
- $72.67m
- $9.76m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 5.78 | 9.38 | 4.33 | 12 | 9.76 |
Cost of Revenue | |||||
Gross Profit | 1.96 | 6.11 | 2 | 9.94 | 7.72 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 39.7 | 37.9 | 45.8 | 48.6 | 40.4 |
Operating Profit | -33.9 | -28.5 | -41.5 | -36.6 | -30.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -38.5 | -33.8 | -52.6 | -48.4 | -41.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -38.5 | -33.8 | -52.6 | -48.4 | -41.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -38.5 | -33.8 | -52.6 | -47.5 | -41.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -44.7 | -38.6 | -52.6 | -47.5 | -41.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,744 | -183 | -84.2 | -34.5 | -1.93 |